![Roman Urfer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Roman Urfer
Directeur Général chez Selonterra, Inc.
Postes actifs de Roman Urfer
Sociétés | Poste | Début | Fin |
---|---|---|---|
NeuroAssets Sàrl | Corporate Officer/Principal | - | - |
Selonterra, Inc.
![]() Selonterra, Inc. BiotechnologyHealth Technology The American company focuses on developing therapies for neurodegenerative disorders such as Parkinson's and Alzheimer's disease. The company uses human genetics, molecular pathway analysis, and gene regulatory networks to identify disease-causing mechanisms and molecular targets to discover effective therapeutics. Selonterra's founders and advisors are experienced scientists and executives in the biotech and pharma industries, and they collaborate with other companies in their network. The company was founded by Anne Urfer-Buchwalder and Roman Urfer, with Roman Urfer serving as CEO since incorporation. | Directeur Général | 01/12/2015 | - |
Fondateur | 01/12/2015 | - |
Historique de carrière de Roman Urfer
Anciens postes connus de Roman Urfer
Sociétés | Poste | Début | Fin |
---|---|---|---|
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - | - |
AGY Therapeutics, Inc.
![]() AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - | - |
M's Science Corp.
![]() M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Directeur/Membre du Conseil | 05/03/2010 | - |
Directeur Technique/Scientifique/R&D | 05/03/2010 | - |
Formation de Roman Urfer
Swiss Federal Institute of Technology | Undergraduate Degree |
University of Basel | Doctorate Degree |
Statistiques
Internationale
Suisse | 5 |
Etats-Unis | 3 |
Japon | 2 |
Opérationnelle
Corporate Officer/Principal | 3 |
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 5 |
---|---|
M's Science Corp.
![]() M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Commercial Services |
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
AGY Therapeutics, Inc.
![]() AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
NeuroAssets Sàrl | |
Selonterra, Inc.
![]() Selonterra, Inc. BiotechnologyHealth Technology The American company focuses on developing therapies for neurodegenerative disorders such as Parkinson's and Alzheimer's disease. The company uses human genetics, molecular pathway analysis, and gene regulatory networks to identify disease-causing mechanisms and molecular targets to discover effective therapeutics. Selonterra's founders and advisors are experienced scientists and executives in the biotech and pharma industries, and they collaborate with other companies in their network. The company was founded by Anne Urfer-Buchwalder and Roman Urfer, with Roman Urfer serving as CEO since incorporation. | Health Technology |
- Bourse
- Insiders
- Roman Urfer
- Expérience